Menlo Park, CA (October 27, 2014) – RenovoRx, a leading developer of innovative solutions for the isolation of blood flow and delivery of fluids to selected sites in the vascular system, today announced that the RenovoRx Board of Directors has appointed Shaun Bagai as Chief Executive Officer and as an additional Member of the RenovoRx Board of Directors. Bagai brings more than 15 years of experience in the medical technology industry.
Bagai joined RenovoRx in June 2014 and in his first few months has been preparing the company for the launch of the RenovoCath RC120. Bagai previously led Global Market Development for HeartFlow, Inc., where he managed HeartFlow’s largest clinical trial and led initial international market development and sales activities. Previously, Bagai was instrumental in developing the European market for renal denervation for Ardian, Inc. (acquired by Medtronic in 2011).
“We are thrilled to have Shaun Bagai to lead RenovoRx,” said Ramtin Agah, RenovoRx Co-Founder. “Bagai has the integrity, leadership, business acumen and the ability to bring RenovoRx to the next level. His vision for how RenovoRx’s technology will be used around the world is exactly what RenovoRx needs as the company enters its next chapter of innovation and growth.”
“RenovoRX has already put together a solid board and a great team,” said new CEO Shaun Bagai. “I am looking forward to helping take this technology to the next level to empower physicians to care for patients who can greatly benefit from selective, targeted fluid delivery.”